Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-2652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir ; volume:13 ; number:4 ; day:8 ; month:11 ; year:2010 ; pages:1 ; date:12.2010
Journal of the International AIDS Society / International AIDS Society ; 13, Heft 4 (8.11.2010), 1, 12.2010
- Urheber
-
Nozza, S.
- Beteiligte Personen und Organisationen
-
Galli, L.
Di Pietro, M.
Mazzotta, F.
Canducci, F.
Pogliaghi, M.
Chiappetta, S.
Galli, A.
Rusconi, V.
Salpietro, S.
Tambussi, G.
Lazzarin, A.
SpringerLink (Online service)
- DOI
-
10.1186/1758-2652-13-S4-P5
- URN
-
urn:nbn:de:1111-2016052060212
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nozza, S.
- Galli, L.
- Di Pietro, M.
- Mazzotta, F.
- Canducci, F.
- Pogliaghi, M.
- Chiappetta, S.
- Galli, A.
- Rusconi, V.
- Salpietro, S.
- Tambussi, G.
- Lazzarin, A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
The use of a darunavir/ritonavir once-daily regimen in two pregnant women
O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults
Use of once-daily raltegravir-based HAART in HIV-infected injection drug users
Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy
A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens
Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naïve patients
ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation
Once-daily regimens were associated with a higher rate of self-chosen discontinuations
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
The use of a darunavir/ritonavir once-daily regimen in two pregnant women
O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults
Use of once-daily raltegravir-based HAART in HIV-infected injection drug users
Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy
A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens
Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naïve patients
ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation
Once-daily regimens were associated with a higher rate of self-chosen discontinuations
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
The use of a darunavir/ritonavir once-daily regimen in two pregnant women
O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults
Use of once-daily raltegravir-based HAART in HIV-infected injection drug users
Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy
A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens
Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naïve patients
ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation
Once-daily regimens were associated with a higher rate of self-chosen discontinuations